Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
NEXT Oncology, San Antonio, Texas, United States
Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli, Italy
Hospital Vall d'Hebron, Barcelona, Spain
Centre Leon Berard, Lyon, Rhône-Alpes, France
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Peninsula and Southeast Oncology, Frankston, Victoria, Australia
Yale University, New Haven, Connecticut, United States
Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States
Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
Istituto Nazionale Tumori Regina Elena Irccs, Rome, Italy
Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center" ( Site 1819), Chernivtsi, Chernivetska Oblast, Ukraine
Rivne Regional Clinical Hospital ( Site 1817), Rivne, Rivnenska Oblast, Ukraine
City of Hope ( Site 0102), Duarte, California, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
New York Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States
New York Presbyterian/Weill Cornell Medical Center, New York, New York, United States
University of San Diego, San Diego, California, United States
Portland Providence Medical Center, Portland, Oregon, United States
Providence St. Vincent Medical Center, Portland, Oregon, United States
National Cancer Center East, Chiba, Japan
National Cancer Center Hospital, Tokyo, Japan
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.